153 related articles for article (PubMed ID: 8782465)
21. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
22. DNA fusion vaccines against B-cell tumors.
Zhu D; Rice J; Savelyeva N; Stevenson FK
Trends Mol Med; 2001 Dec; 7(12):566-72. PubMed ID: 11733220
[TBL] [Abstract][Full Text] [Related]
23. Escherichia coli-based production of a tumor idiotype antibody fragment--tetanus toxin fragment C fusion protein vaccine for B cell lymphoma.
Patel KG; Ng PP; Levy S; Levy R; Swartz JR
Protein Expr Purif; 2011 Jan; 75(1):15-20. PubMed ID: 20851769
[TBL] [Abstract][Full Text] [Related]
24. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
[TBL] [Abstract][Full Text] [Related]
25. Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system.
Yang J; Kanter G; Voloshin A; Michel-Reydellet N; Velkeen H; Levy R; Swartz JR
Biotechnol Bioeng; 2005 Mar; 89(5):503-11. PubMed ID: 15669088
[TBL] [Abstract][Full Text] [Related]
26. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
Caspar CB; Levy S; Levy R
Blood; 1997 Nov; 90(9):3699-706. PubMed ID: 9345055
[TBL] [Abstract][Full Text] [Related]
27. Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.
Morecki S; Levi S; Puyesky Y; Slavin S
Cancer Immunol Immunother; 1995 Oct; 41(4):236-42. PubMed ID: 7489566
[TBL] [Abstract][Full Text] [Related]
28. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
29. B-cell lymphoma idiotypes chimerized by gene targeting can induce tumor immunity.
Selmayr M; Menzel H; Kremer JP; Thierfelder S; Mocikat R
Cancer Gene Ther; 2000 Mar; 7(3):501-6. PubMed ID: 10766357
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
[TBL] [Abstract][Full Text] [Related]
32. Translational development of vaccination strategies in follicular NHL.
Sakamaki I; Qin H; Kwak LW
Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
[TBL] [Abstract][Full Text] [Related]
33. Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma.
Kunkel LA
Cancer Invest; 2004; 22(1):97-105. PubMed ID: 15069767
[No Abstract] [Full Text] [Related]
34. Prime-boost vaccines encoding an intracellular idiotype/GM-CSF fusion protein induce protective cell-mediated immunity in murine pre-B cell leukemia.
Pasquini S; Peralta S; Missiaglia E; Carta L; Lemoine NR
Gene Ther; 2002 Apr; 9(8):503-10. PubMed ID: 11948375
[TBL] [Abstract][Full Text] [Related]
35. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
36. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.
Fredriksen AB; Bogen B
Blood; 2007 Sep; 110(6):1797-805. PubMed ID: 17540847
[TBL] [Abstract][Full Text] [Related]
37. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens.
Biragyn A; Surenhu M; Yang D; Ruffini PA; Haines BA; Klyushnenkova E; Oppenheim JJ; Kwak LW
J Immunol; 2001 Dec; 167(11):6644-53. PubMed ID: 11714836
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
39. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas.
Timmerman JM; Caspar CB; Lambert SL; Syrengelas AD; Levy R
Blood; 2001 Mar; 97(5):1370-7. PubMed ID: 11222382
[TBL] [Abstract][Full Text] [Related]
40. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
